Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

von, Lewinski, D; Kolesnik, E; Tripolt, NJ; Pferschy, PN; Benedikt, M; Wallner, M; Alber, H; Berger, R; Lichtenauer, M; Saely, CH; Moertl, D; Auersperg, P; Reiter, C; Rieder, T; Siller-Matula, JM; Gager, GM; Hasun, M; Weidinger, F; Pieber, TR; Zechner, PM; Herrmann, M; Zirlik, A; Holman, RR; Oulhaj, A; Sourij, H.
Empagliflozin in acute myocardial infarction: the EMMY trial.
Eur Heart J. 2022; 43(41):4421-4432 Doi: 10.1093/eurheartj/ehac494 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Führende Autor*innen der Med Uni Graz
Sourij Harald
von Lewinski Dirk
Co-Autor*innen der Med Uni Graz
Benedikt Martin
Herrmann Markus
Kolesnik Ewald
Pferschy Peter
Pieber Thomas
Reiter Christian
Tripolt Norbert
Wallner Markus
Zechner Peter
Zirlik Andreas

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

AIMS: Sodium-glucose co-transporter 2 inhibition reduces the risk of hospitalization for heart failure and for death in patients with symptomatic heart failure. However, trials investigating the effects of this drug class in patients following acute myocardial infarction are lacking. METHODS AND RESULTS: In this academic, multicentre, double-blind trial, patients (n = 476) with acute myocardial infarction accompanied by a large creatine kinase elevation (>800 IU/L) were randomly assigned to empagliflozin 10 mg or matching placebo once daily within 72 h of percutaneous coronary intervention. The primary outcome was the N-terminal pro-hormone of brain natriuretic peptide (NT-proBNP) change over 26 weeks. Secondary outcomes included changes in echocardiographic parameters. Baseline median (interquartile range) NT-proBNP was 1294 (757-2246) pg/mL. NT-proBNP reduction was significantly greater in the empagliflozin group, compared with placebo, being 15% lower [95% confidence interval (CI) -4.4% to -23.6%] after adjusting for baseline NT-proBNP, sex, and diabetes status (P = 0.026). Absolute left-ventricular ejection fraction improvement was significantly greater (1.5%, 95% CI 0.2-2.9%, P = 0.029), mean E/e' reduction was 6.8% (95% CI 1.3-11.3%, P = 0.015) greater, and left-ventricular end-systolic and end-diastolic volumes were lower by 7.5 mL (95% CI 3.4-11.5 mL, P = 0.0003) and 9.7 mL (95% CI 3.7-15.7 mL, P = 0.0015), respectively, in the empagliflozin group, compared with placebo. Seven patients were hospitalized for heart failure (three in the empagliflozin group). Other predefined serious adverse events were rare and did not differ significantly between groups. CONCLUSION: In patients with a recent myocardial infarction, empagliflozin was associated with a significantly greater NT-proBNP reduction over 26 weeks, accompanied by a significant improvement in echocardiographic functional and structural parameters. CLINICALTRIALS.GOV REGISTRATION: NCT03087773.
Find related publications in this database (using NLM MeSH Indexing)
Humans - administration & dosage
Biomarkers - administration & dosage
Heart Failure - drug therapy
Myocardial Infarction - drug therapy
Natriuretic Peptide, Brain - administration & dosage
Peptide Fragments - therapeutic use
Stroke Volume - administration & dosage
Ventricular Function, Left - administration & dosage

Find related publications in this database (Keywords)
Clinical trial
Randomised controlled trial
Myocardial infarction
Heart failure
© Med Uni Graz Impressum